Double-blind, randomised, multicentre endocrine trial comparing two letrozole doses, in postmenopausal breast cancer patients

European Journal of Cancer

Volumn 35, Issue 2, 1999, Pages 208-213

  Bajetta, E ^a   Zilembo, N ^a   Dowsett, M ^b   Guillevin, L ^c   Di Leo, A ^a   Celio, L ^a   Martinetti, A ^a   Marchiano A ^a   Pozzi, P ^a   Stani, S ^a   Bichisao, E ^d  

^a Div Exp Oncol B   (Italy)

^b ROYAL MARSDEN HOSPITAL   (United Kingdom)

^c AVICENNE HOSPITAL   (France)

^d Medical Department   (Italy)

Author keywords

Aromatase inhibitors; Breast cancer; Letrozole; Oestrogens; Synacthen test

Indexed keywords

AROMATASE INHIBITOR; ESTRADIOL; ESTRONE; FOLLITROPIN; LETROZOLE; LUTEINIZING HORMONE; SEX HORMONE BINDING GLOBULIN;

ADULT; AGED; ARTICLE; BREAST CANCER; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG RESEARCH; DRUG SCREENING; ENDOCRINE FUNCTION; FEMALE; HUMAN; MULTICENTER STUDY; POSTMENOPAUSE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME;

EID: 0033082373     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0959-8049(98)00392-X     Document Type: Article

References (24)

1. Brodie A.M.H., Njar V.C.O. Aromatase inhibitors and breast cancer. Semin Oncol. 23:(4):1996;10-20.
2. Buzdar A.U., Plourde P.V., Hortobagyi G.N. Aromatase inhibitors in metastatic breast cancer. Semin Oncol. 23:(4):1996;28-32.
3. Bhatnagar AS, Häusler A, Schieweck K, Batzi-Hartmann C, Lang M, Trunet P. Estrogen depletion in advanced breast cancer: why, how and where are we going? In Rubens RD, ed. Advanced Breast Cancer: Reassessing Hormonal Therapy. London, Parthenon Publishing, 1996, 21-30.
4. Bajetta E., Zilembo N., Buzzoni R., et al. Endocrinological and clinical evaluation of two doses of formestane in advanced breast cancer. Br J Cancer. 70:1994;145-150.
5. Bajetta E., Zilembo N., Barni S., et al. A multicentre, randomized, pharmacokinetic, endocrine and clinical study to evaluate formestane in breast cancer patients at first relapse: endocrine and clinical results. Ann Oncol. 8:1997;649-654.
6. Bhatnagar AS, Bowman RM, Schieweck K, et al. Letrozole: from test tube to patients. In Mourisden HT, ed. New Options for the Therapy of Advanced Breast Cancer. London, Parthenon Publishing 1996, 9-14.
7. Lipton A., Demers L.M., Harvey H.A., et al. Letrozole (CGS 20 267), a phase I study of a new potent oral aromatase inhibitor of breast cancer. Cancer. 75:1995;2132-2138.
8. Bisagni G., Cocconi G., Scaglione F., Fraschini F., Pfister C., Trunet P.F. Letrozole, a new oral non-steroidal aromatase inhibitor in treating postmenopausal patients with advanced breast cancer. A pilot study. Ann Oncol. 7:1996;99-102.
9. Tominaga T., Ohashi Y., Abe R., et al. Phase II trial of letrozole (a novel oral nonsteroidal aromatase inhibitor) in postmenopausal patients with advanced or recurrent breast cancer. Eur J Cancer. 31A:(Suppl. 5):1995;373.
10. World Health Organisation. Handbook for Reporting Results of Cancer Treatment. Geneva, WHO Offset Publication No. 48, 1979.
11. Hayward J.L., Carbone P.P., Heuson J.C., Kumaoka S., Segaloff A., Rubens R.D. Assessment of response to therapy in advanced breast cancer. Eur J Cancer. 13:1977;89-94.
12. Common Toxicity Criteria. Bethesda, Maryland, National Institute of Health, Cancer Therapy Evaluation Program, Division of Cancer Treatment, 1993.
13. Trunet P.F., Mueller P.H., Girard F., et al. The effects of fadrozole hydrochloride on aldosterone secretion in healthy male subjects. J Clin Endocrinol Metab. 74:1992;571-576.
14. Dowsett M., Goss P.E., Powles T.J., et al. Use of the aromatase inhibitor 4-hydroxyandrostenedione in postmenopausal breast cancer: optimization of therapeutic dose and route. Cancer Res. 47:1987;1957-1961.
15. Santen R.J., Manni A., Harvey H., Redmond C. Endocrine treatment of breast cancer in women. Endocr Rev. 11:1990;221-265.
16. Jacobs S., MacNeill F., Lonning P., Dowsett M., Jones A., Powles T.J. Aromatase activity, serum oestradiol and their correlation with demographic indices. J Steroid Biochem Molec Biol. 41:1992;769-771.
17. Reed M.J., Aherne G.W., Ghilchik M.W. Concentrations of estrone and 4-hydroxyandrostenedione in malignant and normal breast tissue. Int J Cancer. 49:1991;562-565.
18. Lee K., Macaulay M., Nicholls J.E., Detre S., Ashworth A., Dowsett M. An in vivo model of intratumoral aromatase using aromatase-transfected MCF7 human breast cancer cells. Int J Cancer. 62:1995;297-302.
19. Demers L.M., Lipton A., Harvey H.A., et al. The efficacy of CGS 20267 in suppressing estrogen biosynthesis in patients with advanced breast cancer. J Steroid Biochem Mol Biol. 44:1993;687-691.
20. Lamberts S.W.J., Bruining H.A., Marzouk H., et al. The new aromatase inhibitor CGS 16949A suppress aldosterone and cortisol production by human adrenal cells in vitro. J Clin Endocrinol Metab. 69:1989;896-901.
21. Dixon J.M., Love C.D.B., Tucker S. Letrozole as primary therapy for locally advanced breast cancer. Nottingham International Breast Cancer Conference. Breast. 6:1997;245.
22. Dombernowsky P., Smith I., Falkson G., et al. Letrozole, a new oral aromatase inhibitor for advanced breast cancer: double-blind randomized trial showing a dose effect and improved efficacy and tolerability compared with megestrol acetate. J Clin Oncol. 16:1998;453-461.
23. Marty M., Gershanovich M., Campos D. Letrozole, a new potent, selective aromatase inhibitor (AI) superior to aminoglutethimide (AG) in postmenopausal women with advanced breast cancer (ABC) previously treated with antiestrogens. Proc Am Soc Clin Oncol. 16:1997;544.
24. Ingle J.N., Johnson P.A., Suman V.J., et al. A randomized phase II trial of two dosage levels of letrozole as third-line hormonal therapy for women with metastatic breast carcinoma. Cancer. 80:1997;218-224.